<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393861</url>
  </required_header>
  <id_info>
    <org_study_id>0609-11; IUCRO-0166</org_study_id>
    <secondary_id>IUCRO-0166</secondary_id>
    <secondary_id>AVF4003s</secondary_id>
    <nct_id>NCT00393861</nct_id>
  </id_info>
  <brief_title>Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients</brief_title>
  <official_title>Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in
      patients with refractory or relapsed germ cell tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes to look at the established combination of oxaliplatin and bevacizumab as
      used in colorectal cancer in refractory germ cell tumor patients. Oxaliplatin is a drug of
      known activity. Although bevacizumab has no single agent data, it combines dramatically well
      with numerous chemotherapy drugs, such as oxaliplatin increasing response rates and improving
      survival. Furthermore, VEG-F appears to be an important target in germ cell tumors as it does
      in so many other types of solid tumors. We will be using the identical dosages of oxaliplatin
      + bevacizumab as has been utilized in previously treated colorectal cancer, without the
      addition of 5-FU + leucovorin. This dose and schedule has been proven to be safe and
      effective.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Twelve Month Disease-free Survival Rate</measure>
    <time_frame>12 month post completion of treatment</time_frame>
    <description>The percent of patients being disease-free at 12 months after treatment initiation will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (Complete and Partial Response)</measure>
    <time_frame>completion of study, up to 5 years</time_frame>
    <description>The percent of patients having an objective response (complete or partial response) will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission (CR + PR)</measure>
    <time_frame>completion of study, up to 5 years</time_frame>
    <description>Will be examined using Kaplan-Meier estimates. Time from earliest confirmed remission criteria until death or progression will be calculated. If a patient continued to be in remission at the end of the study, they will be censored at their last evaluation in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>completion of study, up to 5 years</time_frame>
    <description>Will be examined using Kaplan-Meier estimates. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <arm_group>
    <arm_group_label>oxaliplatin &amp; bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
    <arm_group_label>oxaliplatin &amp; bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histological or serologic proof of metastatic germ cell neoplasm
             (gonadal or extragonadal primary). Patients with seminoma and non-seminoma are
             eligible, as are women with ovarian germ cell tumors.

          -  Patient's disease must not be amenable to cure with either surgery or chemotherapy in
             the opinion of the investigator.

          -  Patients must have failed initial cisplatin combination chemotherapy administered with
             curative intent such as BEP, EP, VIP, or similar regimens.

          -  Patients should have failed and demonstrated progressive disease with high dose
             chemotherapy such as carboplatin and etoposide. (With the exception of late relapse or
             primary mediastinal non-seminomatous germ cell tumor.

          -  Patients with late relapse or primary mediastinal non-seminomatous germ cell tumors
             must have failed at least 1 salvage chemotherapy regimen.

          -  Patients must have had prior exposure to paclitaxel, gemcitabine, or the combination
             of paclitaxel + gemcitabine.

          -  Patients must have adequate hematologic function (WBC &gt; 4,000/mm3 and platelets &gt;
             100,000/mm3) obtained &lt; 4 weeks prior to registration.

          -  Patients must have adequate hepatocellular function (SGOT &lt; 4 x normal and Bilirubin
             &lt;2.0 mg/dl) obtained &lt; 4 weeks from protocol registration.

          -  Serum Creatinine must be &lt; 2.0 mg/dl obtained &lt; 4 weeks from protocol registration.

          -  Patients must have an ECOG performance status of 0, 1, or 2.

          -  Patients must be at least 28 days post major surgery, open biopsy, or significant
             traumatic injury at time of study registration.

          -  Patients must be at least 7 days post any minor surgical procedure, excluding
             placement of a vascular access device at the time of study registration.

          -  Patients must be at least 18 years old at time of consent.

        Exclusion Criteria:

          -  Patients who have an active, unresolved infection and/or are receiving concurrent
             treatment with parenteral antibiotics are ineligible. Patients are eligible after
             antibiotics have been discontinued for at least 7 days.

          -  Patients may not have any significant bleeding.

          -  Patients with INR &gt; 1.5 are not eligible unless the patient is on anti-coagulants with
             a therapeutic INR between 1.5 and 3. Patients on coumadin are not eligible unless they
             are on low dose coumadin to keep a vascular access device patent.

          -  Patients with a history of arterial thromboses, unstable angina, transient ischemic
             attach (TIA), cerebral vascular accident (CVA), or a myocardial infarction within the
             last 6 months are not eligible.

          -  Patients must not have known CNS metastases. A Head CT or MRI will be performed only
             if clinically indicated.

          -  Patients must not have received any radiotherapy or chemotherapy within 28 days prior
             to study registration, and have recovered from all toxicity from prior treatments.

          -  Patients must not have any prior history of hypertensive crisis or hypertensive
             encephalopathy.

          -  Patients must not have New York Heart Association (NYHA) Grade II or greater
             congestive heart failure.

          -  Patients must not have history of significant vascular disease.

          -  Patients must not have evidence of bleeding diathesis or coagulopathy.

          -  Patients must not have inadequately controlled hypertension (defined as systolic blood
             pressure 150 and/or diastolic blood pressure &gt; 100 mmHg on antihypertensive
             medications).

          -  Patients must not have history of abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess within 6 months prior to study registration.

          -  Patients must not have serious, non-healing would, ulcer or bone fracture.

          -  Patients must not have proteinuria at screening as demonstrated by a urine protein:
             Creatinine (UPC) ratio of â¥ 1.0.

          -  Patients must not have a known sensitivity to any component of bevacizumab.

          -  Patients must not be pregnant or lactating.

          -  Patients must not have grade 3 or 4 neuropathy.

          -  Females of child bearing potential must not be pregnant. A negative pregnancy test is
             required within 7 days prior to beginning treatment.

        NOTE THE FOLLOWING GUIDELINES FOR USE IN THIS PROTOCOL:

          -  Progressive metastatic disease will be documented by the appearance of metastatic
             lesions on PA and lateral chest x-ray, C.T. scan, or other imaging studies, or the
             presence of a rising serum HCG or AFP.

          -  If a rising serum marker is the only evidence of progressive disease, at least 2
             consecutive determinations must be done exhibiting serologic progression and
             alternative causes for increased serum levels of these substances must not be present
             [cross reaction with LH (tested if necessary by testosterone suppression of LH),
             ingestion of marijuana, hepatitis, etc.].

          -  Patients will be considered to have failed a prior regimen if they fail to obtain a
             complete response per RECIST as outlined in section 6.

          -  Patients with clinical situation of growing teratoma (normal or declining markers and
             radiographic or clinical progression) should be considered for surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Einhorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Univeristy School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Univeristy Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania:Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2006</study_first_submitted>
  <study_first_submitted_qc>October 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2006</study_first_posted>
  <results_first_submitted>January 21, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2015</results_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Germ Cell Tumor</keyword>
  <keyword>Germ Cell Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This protocol was based on getting at least 18 evaluable patients. Since the response data had looked promising, an additional 11 patients were added to obtain more accurate estimates of response.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxaliplatin &amp; Bevacizumab</title>
          <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaliplatin &amp; Bevacizumab</title>
          <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Twelve Month Disease-free Survival Rate</title>
        <description>The percent of patients being disease-free at 12 months after treatment initiation will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug.</description>
        <time_frame>12 month post completion of treatment</time_frame>
        <population>All patients enrolled and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin &amp; Bevacizumab</title>
            <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Twelve Month Disease-free Survival Rate</title>
          <description>The percent of patients being disease-free at 12 months after treatment initiation will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug.</description>
          <population>All patients enrolled and received treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.2" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (Complete and Partial Response)</title>
        <description>The percent of patients having an objective response (complete or partial response) will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>completion of study, up to 5 years</time_frame>
        <population>All patients enrolled and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin &amp; Bevacizumab</title>
            <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (Complete and Partial Response)</title>
          <description>The percent of patients having an objective response (complete or partial response) will be estimated with a 90% exact binomial confidence interval for the percent of patients receiving drug per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>All patients enrolled and received treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="14.5" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Remission (CR + PR)</title>
        <description>Will be examined using Kaplan-Meier estimates. Time from earliest confirmed remission criteria until death or progression will be calculated. If a patient continued to be in remission at the end of the study, they will be censored at their last evaluation in the analysis.</description>
        <time_frame>completion of study, up to 5 years</time_frame>
        <population>All patients enrolled and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin &amp; Bevacizumab</title>
            <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Remission (CR + PR)</title>
          <description>Will be examined using Kaplan-Meier estimates. Time from earliest confirmed remission criteria until death or progression will be calculated. If a patient continued to be in remission at the end of the study, they will be censored at their last evaluation in the analysis.</description>
          <population>All patients enrolled and received treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Will be examined using Kaplan-Meier estimates. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis.</description>
        <time_frame>completion of study, up to 5 years</time_frame>
        <population>All patients enrolled and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin &amp; Bevacizumab</title>
            <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Will be examined using Kaplan-Meier estimates. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis.</description>
          <population>All patients enrolled and received treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="5.4" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>beginning of treatment until the end of the study for up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxaliplatin &amp; Bevacizumab</title>
          <description>Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>HEARTBURN/DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION (DYSGEUSIA)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>PAIN - ABDOMEN NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE (ASTHENIA, LETHARGY, MALAISE)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>FEVER (IN THE ABSENCE OF NEUTROPENIA, WHERE NEUTROPENIA IS DEFINED AS ANC &lt;1.0 X 10E9/L)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION/EXTRAVASATION CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>PAIN - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>PAIN - HEAD/HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MOOD ALTERATION - DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE, PULMONARY/UPPER RESPIRATORY - NOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>DYSPNEA (SHORTNESS OF BREATH)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS/ITCHING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence H. Einhorn, M.D.</name_or_title>
      <organization>IndianaU</organization>
      <phone>(317) 944-0920</phone>
      <email>leinhorn@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

